SCHEDULE: Wexford Capital Reduces Nephros Stake

Wexford Capital LP and associated entities have amended their Schedule 13D filing, reporting a decrease in their beneficial ownership of Nephros, Inc. common stock to 2.06%.

Summary

• Wexford Capital LP, Wexford GP LLC, Charles E. Davidson, and Joseph M. Jacobs have filed an amendment (Amendment No. 12) to their Schedule 13D regarding Nephros, Inc. common stock.
• The filing reports a reduction in beneficial ownership by the reporting persons to 2.06% of the outstanding shares, based on 10,860,120 shares outstanding as of August 7, 2026.
• On September 14, 2026, Wexford Capital effected an in-kind distribution of shares from certain entities (WP11, WP Advisors, WPIC2) to their underlying investors.
• Additionally, shares were sold from these entities to Arthur Amron, a director of Nephros, Inc. and former employee of Wexford Capital.
• The reporting persons disclaim beneficial ownership of shares held by the Wexford Entities and WP Advisors, except to the extent of their pecuniary interests.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing, primarily due to the reduction in beneficial ownership and the distribution of shares, indicating a potential shift in investment strategy or a realization of gains by the reporting persons.

Positives

• The transaction involved an in-kind distribution to underlying investors, potentially benefiting those investors.
• Shares were sold to Arthur Amron, a current director of Nephros, Inc., potentially aligning interests.

Negatives

• Wexford Capital and associated entities have reduced their beneficial ownership of Nephros, Inc. common stock to 2.06%.
• The filing indicates a cessation of beneficial ownership exceeding five percent on September 14, 2026.

Risks

• The reduction in beneficial ownership by a significant holder like Wexford Capital could be interpreted as a lack of confidence or a strategic shift, potentially impacting investor sentiment.
• The sale of shares to Arthur Amron, a director, could raise questions about the nature of the transaction and potential conflicts of interest, although it is presented as an arm's length transaction.

Future Outlook

No specific forward-looking statements or guidance were provided in this amendment, which primarily details a change in beneficial ownership.

Management Comments

• "No Distributing Entities shall receive any compensation, directly or indirectly, in connection with the transaction described herein."
• "Each of Wexford Capital, Wexford GP and Messrs. Davidson and Jacobs disclaims beneficial ownership of the shares of Common Stock held by the Wexford Entities and/or WP Advisors, as applicable, and this report shall not be deemed as an admission that they are the beneficial owner of such securities except, in the case of Davidson and Jacobs, to the extent of their respective pecuniary interests therein."

Industry Context

StockSavvy.ai notes that changes in beneficial ownership filings like this Schedule 13D amendment are common for investment firms adjusting their portfolios. The specific transaction here involves an in-kind distribution and a sale to a director, which is less typical than a straightforward sale on the open market.

Related Party Transactions

• Sale of certain shares of common stock from the Distributing Entities to Arthur Amron, a current director of the Issuer and a former employee of Wexford Capital.

Stakeholder Impact

• Shareholders may react to the reduction in beneficial ownership by a significant holder, potentially impacting share price.
• Underlying investors of the Distributing Entities received an in-kind distribution of shares.
• Arthur Amron, a director, acquired shares in the company.

Next Steps

• The reporting persons will continue to monitor the business and affairs of the Company.
• Future filings may be made if circumstances warrant further amendments to the Schedule 13D.

Key Dates

Recommendation

The filing indicates a reduction in beneficial ownership by Wexford Capital, which is a significant event. However, the transaction also involved a distribution to investors and a sale to a director, suggesting a portfolio adjustment rather than a complete divestment or negative outlook. Without further financial or strategic information from Nephros, Inc., a 'hold' recommendation is prudent, pending more clarity on the company's performance and the implications of this ownership change.

Keywords

Nephros Inc, Schedule 13D, Wexford Capital, Beneficial Ownership, Stock Distribution, Insider Transaction, SEC Filing